Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥50 years of age: A randomized trial.
Saved in:
| Title: | Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥50 years of age: A randomized trial. |
|---|---|
| Authors: | Maréchal, Céline1, Lal, Himal2, Heineman, Thomas C2, Poder, Airi3, Ferguson, Murdo4, Enweonye, Igwebuike5, Hervé, Caroline6, Wauters, Dominique6, Oostvogels, Lidia6, Rheault, Paul7, Talli, Jaak8 |
| Source: | Vaccine. Jul2018, Vol. 36 Issue 29, p4278-4286. 9p. |
| Database: | Environment Complete |
Be the first to leave a comment!
